Motivation: Statistical tests for the detection of differentially expressed genes lead to a large collection of p-values one for each gene comparison. Without any further adjustment, these pvalues may lead to a large number of false positives, simply because the number of genes to be tested is huge, which might mean wastage of laboratory resources. To account for multiple hypotheses, these p-values are typically adjusted using a single step method or a step-down method in order to achieve an overall control of the error rate (the so called familywise error rate). In many applications, this may lead to an overly conservative strategy leading to too few genes being flagged.
INTRODUCTION
In recent years, the problem of simultaneous testing of multiple hypotheses has seen new life mostly due to the recent microarray experiments where expression levels of thousands of genes are simultaneously measured and compared in two (or more) tissue types. This old problem has a new twist, namely, the number of comparisons to be made is extremely large, often running into over ten thousands, and there are only a limited number of replications. To complicate things further, there are design limitations, and also present are sources of potential bias so that some preprocessing of the data are typically necessary. As a result, numerous papers have come out in the last five years or so suggesting various methods, both frequentists, as well as, Bayesian, for the detection of differentially expressed genes in microarray experiments. Some of these are novel methods applicable to general multiple testing ( ) while Storey, 2002 , Efron 2004 others (Kerr , 2000 (Kerr , , 2002 Newton , 2001; et al. et al. Ideker , 2000; et al. et al. Efron et al. et al. et al. , 2001; Efron and Tibshirani, 2002; Dudoit , 2002; Lee , 2003; Storey and Tibshirani, 2003; Ge , 2003; Reiner , 2003; Zhao and Pan, 2003 and so on et al. et al. ) are specifically designed for microarray studies, including adaptation of existing methods to suit microarray data. A comprehensive review up to 2002 can be found in Pan (2002) ; also see the literature review in Datta Dudoit (2003) for a comparative review of et al. et al. (2004) . See various error rates of several commonly used multiple testing procedures.
Often times, biologists (practitioners) face the following frustrating situation in dealing with microarray assays involving a large number of genes but a very few replicates. If they attempt to correct for multiple testing using either a familywise error rate control procedure such as the Westfall and Young (1993) Benjamini and (WY hereafter) or an FDR control procedure such as Hochberg (1995) (BH hereafter) they hardly find any "significant" genes. In other words, these procedures, although statistically correct, are often very conservative in practice. Recently, used the notion of empirical Bayes estimation in the context of microarray testing in a novel way. They adjusted a number of t-statistics in such a way that each of the modified statistics had a component that reflected their collective evidence against the complete null hypothesis. The procedure is however calibrated not to reflect a posterior probability, but rather to control the overall familywise error rate under the complete null. They showed that this technique could greatly increase the sensitivity of the entire procedure at the cost of a modest increase in the false discovery rate.
The present proposal is a much more general attempt in using the idea of empirical Bayes for screening multiple cases. The EBS method presented here has the following three distinct advantages over the earlier procedure in : (i) First and foremost, a simple et al. resampling procedure can be implemented to carry out the EBS in its simplest form since the null (marginal) distribution of each p-value is uniform. Thus, EBS offers an automatic screening of the p-values a user may obtain say from an existing univariate (gene by gene) analysis package. Even though the simplest EBS ignores potential dependence between genes, it is shown to be quite robust with respect to cluster dependence in a simulation setting. (ii) It works directly with the p-values. As a result, the underlying tests don't have to be t-tests; in particular they could be F-tests which might arise in certain ANOVA formulation with expression data (Kerr , 2000) . (iii) The empirical Bayes procedure uses nonparametric techniques to et al. estimate the marginal density of the transformed p-values rather than using a parametric model for the prior distribution and is therefore robust against model mis-specification. A penultimate stage of this development was represented in .
The performance of the EBS procedure is compared with benchmark procedure of WY. In addition, we also compare two FDR control procedures, namely, the well known adjustment due to BH and a relatively recent procedure called BUM ( ). We show that Pounds and Morris, 2003 both WY and BH are potentially conservative. While BUM generally has very good sensitivity, it could be quite unstable in terms of FDR and they results could be unreliable for some data sets. Overall, the EBS procedure showed very good sensitivity while maintaining a reasonable FDR in the various simulation settings that we had considered.
Microarray studies are often regarded (and we are of this opinion) a preliminary screening method in detecting interesting genes and any finding from such studies should be further validated by more rigorous laboratory procedures (such as the RT-PCR). On the other hand, a control of some global error rate (such as the familywise error rate, the false discovery rate etc.) is important given the rather large number of hypotheses to be tested. We feel that the proposed EBS accomplishes both these objectives.
The rest of the paper is organized as follows. The development of the empirical Bayes screening procedure is provided in the next section. A number of simulation studies of various differential expression patterns are reported in the Simulation Results section. In all cases, the EBS led to an increase in the overall sensitivity compared to the benchmark WY and the other two competing p-value based methods. The illustrates the EBS Applications to a Cancer Data set section procedure using a data set on colorectal cancer. We show that the EBS was able to pick up additional relevant genes compared to the other three methods. The paper ends with a detailed Discussion section.
STATISTICAL METHODS

The empirical Bayes formulation
Suppose, we have a number of tests of similar structure with associated p-values denoted : ß s 3 " Ÿ 3 Ÿ QÞ Q In microarray studies, would equal the total number of genes (probe sets etc.) on a microarray and for the th gene might be the observed level of significance for a test that 3 : s 3 compares its average expression levels in two tissue types, say normal versus cancer cells. The p-values indicate evidence against the null hypotheses in the sense that the smaller a p-value, the more significant the evidence is that the gene is indeed differentially expressed. In general, it is defined as the chance of observing a value of the test statistic that is as extreme as (e.g., as large as) the value of the test statistic for the sample at hand, when indeed the gene is not differentially expressed. Thus, it is always a function of the sample test statistic and hence a random variable. Under the null hypothesis of no differential expression, is uniformly : s 3 distributed on the interval and therefore is distributed as standard normal
) where is the standard normal c.d.f. (cumulative distribution function). In the R Ð!ß "Ñ F empirical Bayes formulation, we embed these distributions in a larger family of parametric distributions which also support the alternative hypotheses. Because we are considering tests that are of similar structure, one such model would be to assume a distribution for .
Since our goal is to identify cases with "small" -values, we would test a new set of hypotheses :
0, in this model. Since we are faced with simultaneous testing of a (large) number of hypotheses, we might do better by combining evidence of all tests using an empirical Bayes approach (Robbins, 1964; Efron and Morris, 1975 
leading to the following well known expression (see, e.g., Carlin and Louis, p.86) of the posterior mean
Since is the common marginal density of the , we could estimate by a nonparametric 0 D 0
where is the standard normal kernel (density) and is a small positive number, called the 9 2 bandwidth. The parameter is user selectable and there are numerous methods such as 2 likelihood cross validation, asymptotic minimization of the integrated mean squared errors etc. available in various statistical software packages for choosing Alternatively, a visual 2Þ inspection ("eyeballing") of the resulting density plot may suffice in many applications. Since we want each p-value to borrow strength from the smallest p-values we want a longer left tail for the estimated density and therefore it might be better to oversmooth somewhat for greater 0 s K sensitivity. We took this last approach for our application to the cancer data. A bandwidth of 0.7 lead to a smooth left tail even though there were some large negative values (Fig. 1) . D Fig. 1 Substitution of in the above expression of the Bayes estimator leads to the following 0 Ð>Ñ s K formula for the EBE of ) 3
Step down -value calculation p
We would calibrate our screening procedure such that a familywise error rate (FWER) of ! − (0,1) is maintained. This represents the probability of reaching at least one significant conclusion when indeed the complete null hypothesis is true. To that end, we resort to the resampling based step down procedure of Westfall and Young (1993) . Amongst many existing procedures of FWER control, this is generally regarded as one of the best (least conservative).
A compute fter calculating the empirical Bayes estimates given by (1) Step 1: Find the rank orders such that < :
and let .
Step 2: Generate a collection of random variables from the (approximate) null
Step 3 Step 4: Repeat Steps 2 and 3 a large number of times, say and denote the Fß ? ‡ 3 values by ? Ð"Ñß âß ? ÐFÑÞ ‡ ‡ 3 3
Step 5 
!
Step 2 above can be carried out in a variety of ways depending on the situation. In the simplest form, the can be generated by random sampling from and that's what we advocate in D R Ð ! ß " Ñ practice since it provides an automatic procedure In essence, it assumes that assuming the tests Þ (genes) are independent. Although it is not a correct assumption we show through simulation studies in the next section that the performance of the EBS is quite robust even if this assumption is violated. However, more sophisticated choices are sometimes possible if the original data yielding the p-values are available. For example, in the context of a two sample problem (e.g., pooled t-tests), could be obtained by calculating the z-transforms of the D ‡ observed level of significance of the test statistics calculated using randomly resampled or permuted vectors of observations of all gene expressions from the original data (Dudoit . et al 2002 (Dudoit . et al (2004 suggested creating pseudo data sets by resampling the residuals in an ). Datta et al. ANOVA model for the gene expression in multiple tissue types.
Working of the EBS
The "sharing of evidence" or "borrowing of strength" of the EBS procedure can be easily seen from the expression (1) hypothesis will be different from its behavior under the alternative. Generally speaking, in microarray studies will have a fatter left tail than the standard normal density (the null 0 K density). Thus, this term will tend to be smaller than a typical value under the complete null and, together, these terms will make stochastically even smaller than a corresponding value ) s 3 IF under the null. In other words, the degree of stochastic difference will be larger than that using D Ð 0Ñ s 3 K w alone. The term log represents an overall evidence against the complete null for such genes.
As a concrete example, consider the "adenoma versus carcinoma" comparison for the colorectal cancer data considered in the "Applications to a Cancer Data Set" section. A typical alternative in microarray studies is represented in the shape of the empirical density in Fig. 1 . Clearly, 0 s K 0 s K has a tail shape as described in the previous paragraph. the null value of log . We can see that for potentially informative genes (say, those Ð 0 Ñ K w corresponding to negative ), it tends to be below the diagonal line indicating an overall D 3 presence of "differentially expressed genes" corresponding to a given level. D 
SIMULATION RESULTS
In this section, we report the results of a number of simulation studies where we compute various performance measures for screening multiple p-values using both standard WY and EBS as well as the FDR control procedures BH and BUM. These are (i) Sensitivity: proportion amongst differentially expressed genes that were declared significant, (ii) Specificity: proportion amongst non-differentially expressed genes that were not declared significant, (iii) False discovery rate (FDR): proportion amongst genes declared significant that were notdifferentially expressed, (iv) False non-discovery rate (FNR): proportion amongst genes declared not significant that were differentially expressed.
Two sample paired comparisons
We consider a set of simultaneous paired t-tests which can be applicable, for example in studying gene expression levels between two samples hybridized on the same cDNA microarray. For simplicity we assume that the tests are independent. Although this is not likely to hold in the microarray setting, the results are still useful to understand the utility of the empirical Bayes adjustment. Moreover, we subsequently study the performance of the EBS method based on this simple assumption in a dependent data setting.
We consider p-values arising from 2000 one sample t-tests (or equivalently two sample Q oe paired t-tests) with 3 5 and 8 replicates, respectively, where four types of alternative < oe ß ß hypotheses (differential gene expression) patterns are created in terms of means of normal data (with unit variance scale). The data can be thought of as the difference in the log-expression levels of gene expression in two tissue types in the microarray context. A graph of the non-zero means in the four simulated models are shown in Fig. 2 . As can be seen from this figure, the proportion of non-null hypotheses ranges between 2.5% to 13%. In each setting, we simulated data and computed 2000 t-statistics which were converted into p-values using :
where is the observed value of the th -test, . We let . The were generated from i.i.d. , and batches of resamples
F were used. The overall FWER was controlled at %. For each sample, were calculated ! oe & : µ in two ways: (i) using , as described in the algorithmic steps in the previous section (which we ) s refer to as 'EBS'), and (ii) using following the same algorithmic steps but with , :
? oe : s s 3 < 3
? oe : ß : oe ÐD Ñ
where (which we refer to as 'WY'). Note that WY is a standard step-F down procedure that has been in use for maintaining FWER in multiple hypotheses tests (Westfall and Young, 1993) . The results in Table 1 were all based on a somewhat arbitrarily chosen bandwidth of 0.8. Although we do not report the details, other nearby bandwidths 2 oe were also investigated and sensitivity gains over WY were noticed in all cases. For the purpose of comparison we also study the performances of two FDR control procedures BH and BUM (one old, one new) where the FDR threshold level is set at 5%. Ideally, this would also ensure weak control of FWER at 5% (Benjamini and Hochberg, 1995) . For each simulation setting, all four procedures were independently replicated fifty times and the four performance measures were calculated based on the average proportions based on these fifty runs.
The amount of specificity of all procedures under study here were at least 99% in all cases (with the exception of BUM in a few cases) and are not reported further in Table 1.   Table 1 results, which are shown in percentages, clearly show that substantial sensitivity gain was achieved by employing the EBS over the benchmark WY, especially in the low sensitivity region. Overall, EBS compares extremely favorably amongst the competing methods. Even though BUM has decent sensitivity as well, it can break down completely in terms of controlling FDR in cases where a BUM model does not adequately reflect the empirical distribution of the p-values, as shown in Simulation 3. Basically, under this scenario, for , BUM incorrectly < oe $ estimated the proportion of null hypothesis to be 1 for most of the fifty runs. EBS, on the other hand managed to maintain an acceptable level of FDR in all cases that we studied even though it is not explicitly controlled in this procedure. The EBS appears to have the smallest FNR in all cases.
Next, we study the performance of the above EBS method that implicitly assumes that the tests are independent (as incorporated in the resampling stage) in the case of cluster dependent data. Consider, for example, log-transformed data for the th gene generated by .
. oe   # à " Ÿ 4 Ÿ <ß
where is the replication size, denotes the cluster containing gene < M oe M Ð 3 Ñ 3 à " Ÿ 3 Ÿ Q oe #!!!Þ R Ð!ß "Ñ The error terms and are generated from independent and the % % w mean vector were the same as in the simulations above. Biologically speaking, we are . envisioning that genes in a cluster act in consort resulting in correlated expression measures. Basically, (2) ensures that a pair of genes belonging to the same cluster have non-zero correlation; however if they belong to different clusters their expression values are independent or uncorrelated. To see this, consider a pair of genes and . was computed based on fifty runs and in each run we perform step-down calculation using 500 i.i.d. bootstrap replicates from standard normal. In other words, the identical procedure as before was followed without the knowledge that the data was generated this way. We choose three different numbers of clusters (of equal sizes), and The results are reported in "!ß &! #!!Þ Table 2 . For the sake of brevity, we only report the results for Simulations 1 and 3 with sample sizes 3 and 5. The FDR and the FNR of all the procedures appear to be insensitive to the number of clusters while the sensitivity is more variable in the low region. Overall, the performance of EBS appears to be quite robust with respect to dependent tests and it continues to enjoy its superior sensitivity property.
APPLICATIONS TO A CANCER DATA SET
We now illustrate our screening procedure with a real data set on colorectal cancer. This data set was featured in earlier. There were altogether nine Affymetrix chips corresponding to three different patients (individuals) and three tissue types, normal, adenoma and carcinoma. In this paper, we look at a subset of about 10000 genes out of over 12000 genes in the Affymetrix U95 chipset, whose expression levels were judged to be reliable. The initial pvalues (unadjusted) were calculated from an ANOVA model described below applied to this data set.
ANOVA models for expression data
The ANOVA approach (linear models) has become a standard modeling tool to describe the (log-transformed) expression levels of genes in experiments involving multiple tissue types (Kerr , 2000 , Kerr 2002 , Datta and et al. et al., et al. Kerr and Churchill, 2001 expression levels for individuals, genes and varieties, respectively and the interaction term a b MK 3 35 accounts for the variability of expression of the th gene among individuals. It is perhaps more reasonable to assume the individual effect to be random. However for the sake of M 5 simplicity we treat these as fixed effects. Also the independence of the error terms across genes is a simplifying assumption. However, as demonstrated in the earlier simulation example, the procedures based on the independent error assumption continues to have reasonable performance for certain types of dependent errors (cluster dependence). Our primary interest lies in the gene tissue-type interaction which measures the effect of gene in tissue type .
The null hypothesis of no differential expression of gene in two tissue types and is > / Fig. 3 shows the smoothed empirical distributions (i.e., the estimated marginal density of ) 0 s K the normal transforms ( of these p-values for "normal versus adenoma", "normal versus F " Ñ carcinoma" and "adenoma versus carcinoma" comparisons for the colorectal data set. Fig. 3 For each tissue-pair comparison, we compute the p-values for all the genes using the above formulas and then feed them into the EBS procedure based on i.i.d. uniform resampling. We have also ran the other three competing procedures on the same set of p-values. As in the simulation section, we take the overall FWER of for the WY and the EBS and FDR ! oe !Þ!& control at 5% for BH and BUM. In all cases, EBS has flagged more genes compared to other procedure. These are summarized in Table 3 . Note from Fig. 3 that the empirical distribution for the "normal versus adenoma" comparison is very close to the complete null distribution (i.e., standard normal). The BUM method broke down for this case since it estimated the proportion of null hypotheses to be one (see earlier comments about Simulation 3).
Validation
We inspected the results for the normal versus adenoma comparison in more detail. Fig. 4 demonstrates the thresholds (indicated by vertical lines) for the four p-values based procedures under consideration. In each case, genes whose p-values are to the left of the threshold are flagged (declared to be significant). Thus, EBS picked up 29 additional genes that were not flagged by any other procedure. Although we have demonstrated through simulation that indeed the EBS picks up more differentially expressed genes as evident from it superior sensitivity, we wanted to see whether these additional genes contain any meaningful genes. Fig. 4 After searching the published literature, we found that indeed several of these genes have been linked to colorectal or other cancer in the past. We present a selected subset of five genes from this list in Table 4 .
The first gene on this list, CDC2, is a well known cancer gene (CG_ID 278) whose overexpression is colorectal adenocarcinoma is well documented (Kim , 1999) . In a et al. previous study, FUT4 gene was found to be expressed in human colorectal cancer tissues and colorectal cancer cell lines (see Nishihara , 1999) which is further explained in Yazawa et al. et al. (2002) . SPARCL1 is a well known cancer gene (CG_ID 1662) whose down regulation occurs in human non-small cell lung cancer (NSCLC), and also in prostate and colon carcinomas. It has been suggested (using a colon carcinoma model) that Cancer gene LGMN (legumain, CG_ID 2178) could be a target for therapy (Liu , 2003) . Cells overexpressing et al legumain possessed increased migratory and invasive activity in vitro and adopted an invasive and metastatic phenotype in vivo. S100P is a known cancer gene (CG_ID 2860) that has been linked with various cancers such as breast, pancreatic and prostate cancers (Guerreiro , et al. 2000; Sato , 2004; Mousses , 2002) . et al.
et al.
DISCUSSION
In this paper, we propose a novel empirical Bayes screening (EBS) procedure when one needs to decide about a large number of null hypotheses. Unlike the empirical Bayes adjustment of which only applies to studentized test statistics, the EBS procedure can work directly with a set of p-values produced by individual tests. Thus it offers an automatic screening of the p-values a user may obtain from his or her favorite gene by gene analysis software. In addition, the current procedure utilizes the p-values and not the test statistics; therefore, it has broader applicability to other types of tests such as the F-tests or rank tests. For example, in a microarray experiment involving multiple tissue types (e.g., normal, adenoma and carcinoma) one would be able to detect genes that are differentially expressed amongst the various types of tissues (without restricting attention to a particular tissue pair). The EBS procedure screens each p-value not only on its own magnitude but also on the basis of the totality of the p-values (or its empirical distribution). In that sense, each p-value may borrow evidence from other p-values leading to a detection of a greater number of "interesting cases", when the complete null is false, while maintaining a control on the familywise error rate under the complete null.
As stated in the introduction, there are other global statistical approaches such as SAM ) Ideker , 2000 , and VERA ( for the detection of differentially expressed genes in microarray studies. In this paper, we specifically restrict our attention to methods that are based on gene by gene p-values. Three such existing methods have been compared with our proposed method. We conclude this section with a number of additional comments.
Strong versus weak control of FWER
The WY step-down procedure yields strong control of FWER under a subset pivotality condition. This means that even when the complete null is not true, the procedure will declare at least one of the component null hypotheses as positive with probability at most . However, ! this will not be true for EBS which can only be calibrated at the complete null. Since philosophically (as well as algebraically) it uses shared or borrowed evidence from all hypotheses, the non-null distribution of one p-value affects the distribution of all the empirical Bayes estimates. Note that FDR control procedures such as BH or BUM also control the FWER in the weak sense. We feel that for many applications, the strong control requirement is unduly conservative and would recommend using the EBS nevertheless. However, if desired, a modified version of the EBS can be constructed as follows that would have better control of FWER under incomplete null hypotheses at the expense of lower sensitivity. 
Modeling dependencies amongst genes
In this paper, a relatively straightforward analysis of a microarray data set is presented which does not account for gene to gene correlation. While this suffices for the illustration of the EBS procedure as a method of screening a large number of p-values, a more sophisticated data analysis would need to consider a correlation structure for the gene expressions. While the correct correlation structure may be too complicated and nearly impossible to formulate or to estimate on the basis of limited microarray data that is typically available, a good compromise would be to add a random effect term in the ANOVA model (3) corresponding to the cluster a gene belongs to. Of course, this approach would have to assume that the cluster memberships are known which can only be implemented in practice by an initial clustering procedure. This would amount to assuming a constant correlation within each cluster. A parametric bootstrap, generating data from the appropriate normal distributions, will have to be employed in order to carry out the step-down procedure. On the other hand, simulation studies in this paper shows that the EBS using p-value calculation based on independence assumption seems to have reasonable performance under this type of dependence as well.
Other applications
While we propose the EB screening procedure primarily for the detection of differentially expressed genes, it is applicable in any situation where one has to simultaneously decide about a large number of null hypotheses. This is particularly suitable in situations where it is of not a severe consequence to falsely reject some of the null hypotheses in case the complete null is false. In a sense, this can be viewed as an initial screening procedure where the positive results could be investigated further for confirmation. Proteomics (mass spectrometry) data is another example where the problem of feature (or m/z ratio) selection between competing tissue types can be thought of as a simultaneous testing problem. Perhaps one goal might be to use the selected features from a set of training sample to build a classifier. A classifier such as the Random Forest (Breiman, 2001) can handle "extra" variables and therefore this might be a good application even if some m/z ratios that are not important in differentiating the spectra are selected as variables for the classifier along with the important m/z ratios. LGMN responsible for legumain activity 34319_at S100P S100 calcium binding protein P
